Vivo Capital
Gisele Zhang, Ph.D. is an Executive Director at Vivo. She has more than 10 years of industry experience in the life sciences field as a drug discovery scientist, company executive, and venture capitalist. Prior to joining Vivo Capital, she served as Executive Director at 6 Dimensions Capital and as senior associate at WuXi Healthcare Ventures. During her time as a venture capitalist, Dr. Zhang has led and participated in a number of life sciences and pharmaceutical investments both in China and the United States, including Beigene, Viela Bio, Unity Biotech, Kira Pharmaceuticals, Gracell Bio, and M6P Therapeutics. Previously, she was an associate director in the biology department at WuXi Apptec, contributing to preclinical candidate nominations for several acquisition deals.
Dr. Zhang received her B.S. in Cell Biology and Physiology from University of Paris and a Ph.D. in Pathology and Cell Biology from University of Montreal.
This person is not in any offices
Vivo Capital
Founded in 1996, Vivo Capital is a global investment firm focused on healthcare. Vivo has approximately $4.3 billion in assets under management, invested in over 250 public and private companies worldwide. The firm is headquartered in Palo Alto, California, with additional offices in Asia.